Literature DB >> 2957430

Targeted antigen presentation using crosslinked antibody heteroaggregates.

D P Snider, D M Segal.   

Abstract

We have targeted protein antigens to antigen-presenting cells in vitro by using antibody heteroaggregates containing an antibody against a protein antigen covalently crosslinked to an antibody against a target structure on the surface of the antigen-presenting cells. Antigen presentation was assessed by measurement of lymphokine released by antigen-specific T cell hybridomas. Depending on the experimental conditions, the crosslinked antibodies decreased the amount of antigen required to give a response by the hybridomas by factors of 10(2) to 10(3). Enhanced presentation occurred when antigen was targeted to MHC class I and class II molecules, surface immunoglobulin, or Fc gamma receptors on the surface of the murine B cell lymphoma-hybridoma, TA3. An enhancement of antigen presentation also occurred when antigen was targeted to surface IgD, or class I and class II MHC molecules on murine splenic B cells, and when antigen was targeted to class I and class II molecules on irradiated adherent spleen cells. No response was seen when antigen was targeted to Fc gamma R on B cells or adherent spleen cells. The ability of each crosslinked antibody to enhance presentation paralleled the total amount of each that bound to the surface of the antigen-presenting cells. Antigen presentation, mediated by crosslinked antibody, was antigen-specific and I-A restricted. The presentation of one antigen by using crosslinked antibody did not result in enhanced presentation of a second, bystander antigen. These results suggest that a novel means of stimulating immune responses may be possible in vivo, by targeting antigen to surface structures on antigen-presenting cells.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2957430

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  23 in total

1.  The principle of delivery of T cell epitopes to antigen-presenting cells applied to peptides from influenza virus, ovalbumin, and hen egg lysozyme: implications for peptide vaccination.

Authors:  I B Rasmussen; E Lunde; T E Michaelsen; B Bogen; I Sandlie
Journal:  Proc Natl Acad Sci U S A       Date:  2001-08-21       Impact factor: 11.205

2.  Targeting of T-B interaction using heteroconjugate antibody.

Authors:  J L Davignon; M Vallin-Davignon; P L Cohen; R A Eisenberg
Journal:  Immunology       Date:  1991-05       Impact factor: 7.397

3.  Rapid antibody responses by low-dose, single-step, dendritic cell-targeted immunization.

Authors:  H Wang; M N Griffiths; D R Burton; P Ghazal
Journal:  Proc Natl Acad Sci U S A       Date:  2000-01-18       Impact factor: 11.205

4.  Cellular immune response to the antigen administered as an immune complex.

Authors:  S Marusić-Galesić; K Pavelić; B Pokrić
Journal:  Immunology       Date:  1991-04       Impact factor: 7.397

5.  DNA vaccine that targets hemagglutinin to MHC class II molecules rapidly induces antibody-mediated protection against influenza.

Authors:  Gunnveig Grodeland; Siri Mjaaland; Kenneth H Roux; Agnete Brunsvik Fredriksen; Bjarne Bogen
Journal:  J Immunol       Date:  2013-08-16       Impact factor: 5.422

Review 6.  Virus entry and antigen biosynthesis in the processing and presentation of class-II MHC-restricted T-cell determinants of influenza virus.

Authors:  C J Hackett; L C Eisenlohr
Journal:  Immunol Res       Date:  1990       Impact factor: 2.829

Review 7.  Dendritic cell-targeted vaccines--hope or hype?

Authors:  Wolfgang Kastenmüller; Kathrin Kastenmüller; Christian Kurts; Robert A Seder
Journal:  Nat Rev Immunol       Date:  2014-09-05       Impact factor: 53.106

8.  Simultaneous Targeting of Multiple Hemagglutinins to APCs for Induction of Broad Immunity against Influenza.

Authors:  Ane Marie Anderson; Marta Baranowska-Hustad; Ranveig Braathen; Gunnveig Grodeland; Bjarne Bogen
Journal:  J Immunol       Date:  2018-02-02       Impact factor: 5.422

9.  Antigen-bound C3b and C4b enhance antigen-presenting cell function in activation of human T-cell clones.

Authors:  J Arvieux; H Yssel; M G Colomb
Journal:  Immunology       Date:  1988-10       Impact factor: 7.397

10.  Antigen Targeting to Human HLA Class II Molecules Increases Efficacy of DNA Vaccination.

Authors:  Gunnveig Grodeland; Agnete Brunsvik Fredriksen; Geir Åge Løset; Elisabeth Vikse; Lars Fugger; Bjarne Bogen
Journal:  J Immunol       Date:  2016-09-26       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.